Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;18(4):844-8.
doi: 10.1208/s12248-016-9935-9. Epub 2016 May 27.

Cell-Based Therapies Formulations: Unintended components

Fouad Atouf  1
Affiliations
Review

Cell-Based Therapies Formulations: Unintended components

Fouad Atouf. AAPS J. 2016 Jul.

Erratum in

Abstract

Cell-based therapy is the fastest growing segment of regenerative medicine, a field that promises to cure diseases not treated by other small molecules or biological drugs. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body's own capacity to regenerate damaged or diseased tissue. Some of the challenges in controlling the quality of the finished cell-therapy product relate to the use of a variety of raw materials including excipients, process aids, and growth promotion factors. The quality of these materials is critical for ensuring the safety and quality of the finished therapeutic products. This review will discuss some of the challenges and opportunities associated with the qualification of excipients as well as that of the ancillary materials used in manufacturing.

Keywords: ancillary material; cell-based therapy; excipient; formulation.

PubMed Disclaimer

Comment on

References

    1. <1043> Ancillary materials for cell, gene, and tissue engineered products. In: USP38-NF33. Rockville, MD: US Pharmacopeial Convention; 2016:896.
    1. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs), April 2008. Available at the Food and Drug Administration Web site. http://www.fda.gov, Accessed April 28, 2016
    1. Sakamoto N, Tsuji K, Muul LM, Lawler AM, Petricoin EF, Candotti F, et al. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood. 2007;110(2):501–8. doi: 10.1182/blood-2007-01-066522. - DOI - PMC - PubMed
    1. Guidance for industry: nonclinical studies for the safety evaluation of pharmaceutical excipients, May 2005. Available at the Food and Drug Administration Web site. http://www.fda.gov, Accessed April 28, 2016
    1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q8 Pharmaceutical Development (R2), August 2009. Available at the ICH website: http://www.ich.org, Accessed April 28, 2016